After having been diagnosed with myeloma in 2019, Vincent Claus got in touch with MPE and joined the Taskforce. In 2022, he joined the Advocate Development Programme (ADP) and has since then been involved in many patient advocacy efforts such as SISAQOL-IMI. Recently with the support of MPE, he launched a specific support group for younger myeloma patients (European Young Myeloma Patients Group). His main fields of interest are the youngest myeloma population, lobbying for early(er) diagnosis and equal treatment approaches across Europe.
Join our webinar “The generics market in Europe and implications for cancer treatment and care”
Myeloma Patients Europe (MPE) will hold a webinar on the generics market in Europe and implications for cancer treatment and care on Monday 30th March from 17:00 – 18:30 CET.…